U.S. License Holder:
Regeneron Pharmaceuticals
Date of License:
November-18-2011
Last Update:
Nov-15-2023
FDA-Approved Indications
EYLEA (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
Neovascular (Wet) Age-Related Macular Degeneration (AMD);
Macular Edema Following Retinal Vein Occlusion (RVO);
Diabetic Macular Edema (DME);
Diabetic Retinopathy (DR);
Retinopathy of Prematurity (ROP).
aBLA / 505(b)(2) Activity
aBLA / 505(b)(2) Accepted by FDA
M710: Biocon (Mylan) / Momenta (October-2021) FYB203: Formycon / Klinge Biopharma (June-2023) CT-P42: Celltrion (June-2023) ABP 938: Amgen (October-2023)
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Yesafili® (Biocon) (September-2023 in the EU; November-2023 in the UK)
Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
N
IPR Status
IPR Not Instituted; Request for Rehearing Withdrawn
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
Terminated Prior to Institution Decision
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Terminated Prior to Institution Decision at Petitioner's Request)
IPR Status
Terminated Prior to Institution Decision at Petitioner's Request
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
No Decision
IPR Status
Administratively Closed, No Decision
U.S. Patent No.
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Chengdu Kanghong Biotechnology Co., Ltd.; Bejing Kanghong Biomedical Co. Ltd.; Chengdu Kanghong Pharmaceutical Group Co. Ltd.
§ 102 Challenge
Y: Claims 1-18
Claim Types Challenged Under § 102
Formulation
§ 102 Challenge Instituted
Terminated Prior to Institution Decision
§ 103 challenge
Y: Claims 1-18
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Terminated Prior to Institution Decision
IPR Status
Terminated Prior to Institution Decision (Petitioner Requested Dismissal)
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1334
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Pending
U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson
§ 102 Challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1395
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1395
IPR Status
Joined with IPR2021-00880; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)
IPR Status
Joined with IPR2021-00881; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Apotex Inc.; Apotex Corp.; Apotex Pharmaceutical Holdings Inc.; Aposhem Delaware Holdings Corporation
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)
IPR Status
Joined with IPR2021-00881; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Apotex Inc.; Apotex Corp.; Apotex Pharmaceutical Holdings Inc.; Aposhem Delaware Holdings Corporation
§ 102 Challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1395
IPR Status
Joined with IPR2021-00880; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Pending
U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Apotex Inc.; Apotex Corp.; Apotex Pharmaceutical Holdings Inc.; Aposhem Delaware Holdings Corporation
§ 102 Challenge
Y: Claims 1-5, 8-11, 14, 26-30
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
N
§ 103 challenge
Y: Claims 6, 7, 12, 13
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
IPR Status
IPR Not Instituted
U.S. Patent No.
10,857,205 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1-3
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
N
§ 103 challenge
Y: Claims 1-3
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims Prior to Institution Decision)
IPR Status
IPR Not Instituted Due to Disclaimer
U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1-18
Claim Types Challenged Under § 102
Formulation
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-18
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
IPR Status
Instituted, Pending; Joined with IPR2022-01225
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
IPR Status
Instituted, Pending; Joined with IPR2022-01226
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
IPR Status
Instituted, Pending; Joined with IPR2022-01226
U.S. Patent No.
10,406,226 (Method of Manufacturing VEGF Antagonist Fusion Proteins)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-4
Claim Types Challenged Under § 103
Manufacturing
§ 103 Challenge Instituted
N
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims Prior to Institution Decision)
IPR Status
Institution Denied Due to Disclaimer of All Challenged Claims
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 13-16, 20, 22-24, 29-32, 46-47
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
N (Claims Disclaimed)
§ 103 challenge
Y: Claims 10-33
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y: Claims 10-12, 17-19, 21, 25-28, 33 (Other Claims Disclaimed)
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (In Part- Claims 13-14, 22, 29-30 Disclaimed Prior to Petition Filing; Claims 15-16, 20, 23-24, 31
IPR Status
Instituted (Claims 10-12, 17-19, 21, 25-28, 33), Pending; Claims 13-16, 20, 22-24, 29-32, 46-47 Disclaimed
U.S. Patent No.
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 1-5, 8-11, 15-17, 20-21, 24, 26-30
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Awaiting Institution Decision
§ 103 challenge
Y: Claims 1-14, 16-23, 25-30
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Awaiting Institution Decision
IPR Status
Awaiting Institution Decision
U.S. Patent No.
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 1-18
Claim Types Challenged Under § 102
Formulation
§ 102 Challenge Instituted
Awaiting Institution Decision and Joinder
§ 103 challenge
Y: Claims 1-18
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Awaiting Institution Decision and Joinder
IPR Status
Awaiting Institution Decision; Motion for Joinder with IPR2023-00462 Pending
U.S. Patent No.
10,828,345 (Use of a VEGF Antagonsit to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Chengdu Kanghong Biotechnology Co., Ltd.; Bejing Kanghong Biomedical Co. Ltd.; Chengdu Kanghong Pharmaceutical Group Co. Ltd.
§ 102 Challenge
Y: Claims 1-11
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Terminated Prior to Institution Decision
§ 103 challenge
Y: Claims 1-11
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Terminated Prior to Institution Decision
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Petitioner Requested Dismissal)
IPR Status
Terminated Prior to Institution Decision (Petitioner Requested Dismissal)
U.S. Patent No.
10,857,231 (Formulations of VEG Antagonist Fusion Proteins and Method of Manufacturing Them)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-4, 6-11, 18-21, 27-32, 41-45, 58-59
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
N
IPR Status
Challenges Include Written Description (Claims 1-11, 17-21, 27-32, 41-53, 58-67), Enablement (Claims 1-11, 17-21, 27-32, 41-53, 58-67), and Indefiniteness (Claims 1-11, 17-21, 27-32, 41-53, 58-67); Institution Denied
U.S. Patent Litigations
PACER
Case No(s):
U.S. Patent Nos.
5,688,688 (Vector for Expression of a Polypeptide in a Mammalian Cell)
Plaintiffs
Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Grifols Worldwide Operations Limited
Defendants
Regeneron Pharmaceuticals, Inc.
Status
Judgment of Non-Infringement and Order of Dismissal
BPCIA
N
U.S. Patent Nos.
9,220,631 (Syringe)
Plaintiffs
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Defendants
Regeneron Pharmaceuticals, Inc.
Status
Case Stayed Pending Federal Circuit Appeal of Decision in IPR2021-00816
BPCIA
N
U.S. Patent Nos.
7,070,959 (Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties) 9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,816,110 (CHO Integration Sites and Uses Thereof) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,406,226 (Method of Manufacturing VEGF Antagonist Fusion Proteins) 10,415,055 (Enhanced Expression and Stability Regions) 10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,857,205 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 10,973,879 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,186,625 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,332,771 (Serum-Free Cell Culture Medium)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Mylan Pharmaceuticals Inc.; Biocon Biologics Inc.; Amgen USA, Inc. (Intervenor)
Status
Case Ongoing
BPCIA
Y
U.S. Patent Nos.
7,070,959 (Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties) 9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,315,281 (System and Methods for Use in Dispensing Biopharmaceutical Materials) 9,816,110 (CHO Integration Sites and Uses Thereof) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,415,055 (Enhanced Expression and Stability Regions) 10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,312,936 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,332,771 (Serum-Free Cell Culture Medium) 11,459,374 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,472,861 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,485,770 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,505,593 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,525,833 (Hydrophobic Interaction Chromatography-Coupled Native Mass Spectrometry for Antibody Analysis) 11,535,663 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,542,317 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,548,932 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,555,176 (Cell Culture Medium for Eukaryotic Cells) 11,559,564 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,707,506 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,732,024 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,753,459 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,769,597 (Methods of Associating Genetic Variants with a Clinical Outcome in Patients Suffering from Age-Related Macular Degeneration Treated with Anti-VEGF) 11,788,102 (CHO Integration Sites and Uses Thereof) 11,793,926 (Medical Device Packaging and Related Methods)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Celltrion, Inc.
Status
Case Ongoing
BPCIA
Y
